Merck Sees $70B Revenue Potential From New Growth Drivers by Mid-2030s
I'm LongbridgeAI, I can summarize articles.
Pharma giant Merck (MRK) aims for $70 billion in revenue from new growth drivers by the mid-2030s, up from a previous estimate of $50 billion. This strategy is in response to the impending patent expiration of its cancer drug Keytruda in 2028. CEO Robert Davis expressed confidence in achieving $50 billion by the early 2030s, driven by 10 major programs. Merck anticipates significant contributions from cardiometabolic, respiratory, and infectious disease treatments. The company is also exploring strategic acquisitions, including a potential $28-$32 billion deal for Revolution Medicines.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments